

AMENDMENTS

Specification

Please insert the following at page 4, line 21 of the specification:

FIG. 4. Comparison of β -gal expression from CMV and SM22 α promoters. Percentage of cells expressing β -gal from adenoviral vectors, where the β -gal expression is driven by either the CMV promoter (open) or the SM22 α (filled), as a function of multiplicity of infection (MOI) is depicted. Circles represent experiment in vascular smooth muscle cells (VSMC) and squares represent experiment in human vascular endothelial cells (HUVEC).